Reni Benjamin
Stock Analyst at JMP Securities
(1.45)
# 3,273
Out of 4,732 analysts
158
Total ratings
38.73%
Success rate
-12.56%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Reni Benjamin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BPMC Blueprint Medicines | Reiterates: Market Outperform | $125 | $110.05 | +13.58% | 19 | Jan 15, 2025 | |
| INCY Incyte | Reiterates: Market Perform | n/a | $71.93 | - | 26 | Jan 14, 2025 | |
| HOWL Werewolf Therapeutics | Maintains: Market Outperform | $12 → $4 | $1.33 | +200.75% | 5 | Jan 14, 2025 | |
| BCYC Bicycle Therapeutics | Maintains: Market Outperform | $32 → $26 | $13.34 | +94.90% | 12 | Dec 18, 2024 | |
| STRO Sutro Biopharma | Reiterates: Market Outperform | $17 | $2.01 | +745.77% | 9 | Dec 11, 2024 | |
| PRLD Prelude Therapeutics | Reiterates: Market Outperform | $7 → $4 | $1.05 | +280.95% | 3 | Dec 11, 2024 | |
| LVTX LAVA Therapeutics | Downgrades: Market Perform | $6 | $0.94 | +538.30% | 6 | Dec 11, 2024 | |
| KURA Kura Oncology | Reiterates: Market Outperform | $32 | $7.26 | +340.77% | 8 | Nov 19, 2024 | |
| SANA Sana Biotechnology | Downgrades: Market Perform | n/a | $3.16 | - | 4 | Nov 5, 2024 | |
| TIL Instil Bio | Initiates: Market Perform | n/a | $20.97 | - | 1 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $32 | $19.03 | +68.16% | 1 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $5 | $0.49 | +914.20% | 8 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $15 → $2 | $1.31 | +52.67% | 4 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $13.49 | - | 7 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $25 → $23 | $5.91 | +289.17% | 10 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.82 | - | 6 | Jan 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.91 | - | 3 | Jun 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $8 → $4 | $2.25 | +77.78% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $4.33 | - | 4 | Nov 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $28 → $17 | $5.07 | +235.31% | 3 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.53 | - | 2 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.55 | - | 3 | Nov 15, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | n/a | $7.37 | - | 4 | Jun 14, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $3.00 | - | 2 | Feb 7, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $16 | $0.58 | +2,659.10% | 1 | Oct 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $10 | $16.02 | -37.58% | 2 | Oct 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $22 → $12 | $29.55 | -59.39% | 1 | Sep 25, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $10.27 | - | 1 | Nov 15, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.39 | - | 2 | Nov 10, 2017 |
Blueprint Medicines
Jan 15, 2025
Reiterates: Market Outperform
Price Target: $125
Current: $110.05
Upside: +13.58%
Incyte
Jan 14, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $71.93
Upside: -
Werewolf Therapeutics
Jan 14, 2025
Maintains: Market Outperform
Price Target: $12 → $4
Current: $1.33
Upside: +200.75%
Bicycle Therapeutics
Dec 18, 2024
Maintains: Market Outperform
Price Target: $32 → $26
Current: $13.34
Upside: +94.90%
Sutro Biopharma
Dec 11, 2024
Reiterates: Market Outperform
Price Target: $17
Current: $2.01
Upside: +745.77%
Prelude Therapeutics
Dec 11, 2024
Reiterates: Market Outperform
Price Target: $7 → $4
Current: $1.05
Upside: +280.95%
LAVA Therapeutics
Dec 11, 2024
Downgrades: Market Perform
Price Target: $6
Current: $0.94
Upside: +538.30%
Kura Oncology
Nov 19, 2024
Reiterates: Market Outperform
Price Target: $32
Current: $7.26
Upside: +340.77%
Sana Biotechnology
Nov 5, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $3.16
Upside: -
Instil Bio
Nov 4, 2024
Initiates: Market Perform
Price Target: n/a
Current: $20.97
Upside: -
Nov 4, 2024
Initiates: Market Outperform
Price Target: $32
Current: $19.03
Upside: +68.16%
Sep 16, 2024
Reiterates: Market Outperform
Price Target: $5
Current: $0.49
Upside: +914.20%
Jul 26, 2024
Maintains: Market Outperform
Price Target: $15 → $2
Current: $1.31
Upside: +52.67%
Jul 23, 2024
Initiates: Market Perform
Price Target: n/a
Current: $13.49
Upside: -
Jun 20, 2024
Maintains: Market Outperform
Price Target: $25 → $23
Current: $5.91
Upside: +289.17%
Jan 5, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $1.82
Upside: -
Jun 27, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $0.91
Upside: -
Aug 8, 2022
Maintains: Market Outperform
Price Target: $8 → $4
Current: $2.25
Upside: +77.78%
Nov 12, 2020
Upgrades: Market Perform
Price Target: n/a
Current: $4.33
Upside: -
Nov 10, 2020
Downgrades: Outperform
Price Target: $28 → $17
Current: $5.07
Upside: +235.31%
Dec 3, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $2.53
Upside: -
Nov 15, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $2.55
Upside: -
Jun 14, 2019
Reinstates: Outperform
Price Target: n/a
Current: $7.37
Upside: -
Feb 7, 2019
Upgrades: Market Perform
Price Target: n/a
Current: $3.00
Upside: -
Oct 22, 2018
Maintains: Outperform
Price Target: $20 → $16
Current: $0.58
Upside: +2,659.10%
Oct 12, 2018
Maintains: Outperform
Price Target: $11 → $10
Current: $16.02
Upside: -37.58%
Sep 25, 2018
Downgrades: Outperform
Price Target: $22 → $12
Current: $29.55
Upside: -59.39%
Nov 15, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $10.27
Upside: -
Nov 10, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $0.39
Upside: -